Innosphera Pharma
San Diego, United States· Est.
First‑in‑class oral GPR84 modulator for IPF with a lipid‑mimetic platform targeting fibrosis and metabolic disease.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
First‑in‑class oral GPR84 modulator for IPF with a lipid‑mimetic platform targeting fibrosis and metabolic disease.
Pulmonary FibrosisInflammatory DiseasesMetabolic Disorders
Technology Platform
Small‑molecule GPCR modulators using a lipid‑mimetic design to achieve rapid lung tissue uptake and balanced GPR84 antagonism/GPR40 agonism for anti‑fibrotic and metabolic effects.
Opportunities
First‑in‑class oral GPR84 modulator for IPF with a strong safety profile, plus expansion into high‑growth cardiometabolic markets.
Risk Factors
Clinical development risk for novel GPCR target, competition from established IPF therapies, and need for substantial financing to advance trials.
Competitive Landscape
Competes with pirfenidone, nintedanib, and emerging GPR84 antagonists; differentiation lies in oral dosing, lipid‑mimetic delivery, and broader metabolic indications.